Acute and chronic effects of biliopancreatic diversion with duodenal switch surgery on plasma visfatin and apelin levels in patients with severe obesity

Obesity Surgery

Volumn 23, Issue 11, 2013, Pages 1806-1814

  Caron Cantin, Sarah Maude ^a,b   Martin, Julie ^a,b   Bastien, Marjorie ^a,b   Munkonda, Mercedes Nancy ^a,b   Lu, Huiling ^a,b   Cianflone, Katherine ^a,b   Moustarah, Fady ^a,b   Biertho, Laurent ^a,b   Marceau, Simon ^a,b   Hould, Frédéric Simon ^a,b   Bussières, Jean ^a,b   Poirier, Paul ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Apelin; Bariatric surgery; Severe obesity; Visfatin

Indexed keywords

ADIPOCYTOKINE; APELIN; C REACTIVE PROTEIN; GLUCOSE; INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BILIOPANCREATIC BYPASS; BODY MASS; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; APOLIPOPROTEINS B; BILIOPANCREATIC DIVERSION; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CYTOKINES; DUODENUM; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY, MORBID; QUEBEC; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84885470739     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-0952-9     Document Type: Article

References (43)

1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i-253
2. Deitel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg. 2003;13:329-30.
3. Tjepkema M. Adult obesity. Health Rep. 2006;17:9-25.
4. Renquist K. Obesity classification. Obes Surg. 1998;8:480.
5. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med. 2003;163:2146-8.
6. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415.
7. Franz MJ, VanWormer JJ, Crain AL, et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755-67.
8. Fobi MA. Surgical treatment of obesity: a review. J Natl Med Assoc. 2004;96:61-75.
9. Marceau P, Biron S, Hould FS, et al. Duodenal switch: long-term results. Obes Surg. 2007;17:1421-30.
10. Biron S, Hould FS, Lebel S, et al. Twenty years of biliopancreatic diversion: what is the goal of the surgery? Obes Surg. 2004;14:160-4.
11. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-93.
12. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
13. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347-55.
14. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-30.
15. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911-6.
16. Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91:1578-81.
17. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91:3165-70.
18. Tan BK, Chen J, Digby JE, et al. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab. 2006;91:5022-8.
19. Varma V, Yao-Borengasser A, Rasouli N, et al. Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 2007;92:666-72.
20. Oki K, Yamane K, Kamei N, et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 2007;67:796-800.
21. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-58.
22. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251:471-6.
23. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005;146:1764-71.
24. Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002;91:434-40.
25. Chen MM, Ashley EA, Deng DX, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation. 2003;108:1432-9.
26. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279:26274-9.
27. Heinonen MV, Purhonen AK, Miettinen P, et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005;130:7-13.
28. Krzyzanowska K, Mittermayer F, Krugluger W, et al. Increase in visfatin after weight loss induced by gastroplastic surgery. Obesity (Silver Spring). 2006;14:1886-9.
29. de Luis DA, Izaola O, Conde R, et al. Visfatin levels in female, morbid, nondiabetic obese patients after biliopancreatic diversion surgery. Surg Obes Relat Dis. 2011;7:195-8.
30. Castan-Laurell I, Vitkova M, Daviaud D, et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008;158:905-10.
31. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, et al. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg. 2009;19:1574-80.
32. Martin J, Bergeron S, Pibarot P, et al. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Can J Cardiol 2013. doi: 10.1016/j.cjca.2012.11. 010.
33. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
34. Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15-26.
35. Telejko B, Kuzmicki M, Wawrusiewicz-Kurylonek N, et al. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus. Diabetes Res Clin Pract. 2010;87:176-83.
36. Garcia-Fuentes E, Garcia-Almeida JM, Garcia-Arnes J, et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring). 2007;15:2391-5.
37. Bo S, Ciccone G, Baldi I, et al. Plasma visfatin concentrations after a lifestyle intervention were directly associated with inflammatory markers. Nutr Metab Cardiovasc Dis. 2009;19:423-30.
38. de Luis DA, Gonzalez SM, Conde R, et al. Effect of a hypocaloric diet on serum visfatin in obese non-diabetic patients. Nutrition. 2008;24:517-21.
39. Heinonen MV, Laaksonen DE, Karhu T, et al. Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis. 2009;19:626-33.
40. Japp AG, Cruden NL, Amer DA, et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;52:908-13.
41. Castan-Laurell I, Dray C, Attane C, et al. Apelin, diabetes, and obesity. Endocrine. 2011;40:1-9.
42. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-7.
43. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41.